Literature DB >> 6183354

Immunoregulatory factors derived from human tumors. II. Partial purification and further immunobiochemical characterization of a human sarcoma-derived immunosuppressive factor expressing HLA-DR and immunoglobulin-related determinants.

J A Roth, B A Osborne, R S Ames.   

Abstract

An immunoregulatory factor (IRF) that suppresses Con A-mediated peripheral blood mononuclear cell (PBM) proliferative responses was partially purified by DEAE anion exchange chromatography and affinity chromatography from a 3 M KCl extract of a human liposarcoma. The factor (m.w. = 70K) co-purified with albumin, monitored by two-dimensional gel electrophoresis, and demonstrated a heterogeneous isoelectric point (pI 7.6-7.8). Xenoantisera produced against the DEAE-purified fraction and coupled to Affigel 10 removed suppressive activity that could subsequently be eluted by glycine-HCl, pH 3.5. An anti-albumin column partially removed activity, but the unbound 70K factor could still be detected in the column effluent. A xenoantiserum to this 70K effluent coupled to acrylamide beads completely removed the immunosuppressive activity in immunodepletion experiments. Further direct binding enzyme-linked immunoassays (ELISA) and solid-phase immunoabsorption experiments with monoclonal antibodies to human anti-HLA-DR framework determinants and a constant region of the IgM mu-chain demonstrated determinants on the 70K factor recognized by these antibodies.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6183354

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.

Authors:  H Fujiwara; T Hamaoka
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

Review 2.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Comparison of transforming growth factor beta and a human tumour-derived suppressor factor.

Authors:  S S Somers; J F Dye; P J Guillou
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Abnormalities of T cells isolated from mediastinal lymph nodes and peripheral blood of patients with lung carcinoma: deficit in PHA-induced expression of HLA class II antigens and in autologous mixed lymphocyte reactions.

Authors:  F Indiveri; I Pierri; S Rogna; A Poggi; R Romano; A Tavano; G Ratto; G Motta; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes.

Authors:  D Taramelli; A Mazzocchi; C Clemente; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 7.  Immunobiology of complete molar pregnancy and gestational trophoblastic tumor.

Authors:  R S Berkowitz; S A Umpierre; S Taylor-Emery; D P Goldstein; D J Anderson
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

8.  Purification and immunologic reactivity of Hymenolepis diminuta surface antigens.

Authors:  S Krawczuk; W Rode; B Machnicka
Journal:  Parasitol Res       Date:  1990       Impact factor: 2.289

9.  In vivo delayed rejection of tumors and inhibition of delayed-type hypersensitivity by HT-29 human colonic adenocarcinoma cell line.

Authors:  G J Pommier; F L Garrouste; D Bettetini; J M Culouscou; M M Remacle-Bonnet
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  Depression of cell-mediated immunity by tumour cell products: induction of resistance by immunotherapeutically active extracts of bovine ocular squamous cell carcinoma.

Authors:  M Nelson; D S Nelson; V K Kuchroo; P B Spradbrow; P A Jennings
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.